Dr. Chan on Trial of Cabozantinib in Neuroendocrine Tumors

Jennifer Chan, MD, MPH
Published: Wednesday, Nov 15, 2017



Jennifer Chan, MD, MPH, senior physician, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses a trial of cabozantinib (Cabometyx) in neuroendocrine tumors (NETs).

A phase II trial in patients with carcinoid and pancreatic NETs showed that treatment with cabozantinib was associated with objective tumor responses, as well as encouraging progression-free survival.

Chan says there is ongoing work to evaluate cabozantinib in a larger trial.
 


Jennifer Chan, MD, MPH, senior physician, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses a trial of cabozantinib (Cabometyx) in neuroendocrine tumors (NETs).

A phase II trial in patients with carcinoid and pancreatic NETs showed that treatment with cabozantinib was associated with objective tumor responses, as well as encouraging progression-free survival.

Chan says there is ongoing work to evaluate cabozantinib in a larger trial.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High CancersAug 29, 20182.0
Community Practice Connections™: 1st Annual School of Nursing Oncology™Oct 31, 20181.5
Publication Bottom Border
Border Publication
x